Skip to content

latest news

Medicines Optimisation Centricity – Getting It Right

Petersfield, Hampshire, 01 November 2023, Aspire Pharma Ltd initiated and funded the set-up of a series of round table events to discuss Medicines Optimisation Centricity. These events, facilitated by Wilmington Healthcare, as a data intelligence agency, brought together a number of NHS thought leaders from a wide range of disciplines, and led to the creation of a White Paper on medicines optimisation.

The White Paper focuses on the NHS’ approach to providing engagement, choice, and access to medicines in a timely manner. There is a need for the NHS and pharmaceutical businesses to work collaboratively to ensure a patient centric approach is established, with a shared understanding of individual patients. With the right resources, tools, and knowledge, we can help lift barriers in patient care.

Medicines optimisation looks at the value medicines deliver; that they are both clinically and cost effective. Ensuring patients get the correct medicine, and dose, for the correct indication1, is not always easy. Effective medicines optimisation requires a collaborative approach by those responsible for delivering healthcare to the patient, including the patient themselves1.

Aspire has long sought to identify opportunities which bring innovative solutions for the benefit of patients, using their expertise to develop strong partnerships with payors, providers, and healthcare professionals.

Together, these partnerships can help deliver a breadth and depth of knowledge to assist in customer and patient centricity, that meets the unmet needs of every patient; thus, making a difference in the lives of patients­­­­ through the development and supply of innovative products and medicines throughout the world.

Richard Condon, CEO at Aspire said: “I would like to congratulate our partners involved in the Medicines Optimisation Centricity Project, which is an excellent example of where we have identified a problem, become co-partners, and worked collaboratively at the highest levels to find a solution.

“This project puts patient care at the top of the agenda and will help lead to better access, value and choice for the NHS.”

The Meds Ops Centricity – It’s Time to Optimise Medicines Optimisation White Paper can be found at: https://www.hsj.co.uk/integrated-care/its-time-to-optimise-medicines-optimisation/7034815.article#.ZG98K1eQAU4.linkedin.

Here is a direct link to the White Paper: https://meds-ops-centricity.co.uk/

Aspire Pharma initiated and funded the set-up of a series of round table events to discuss Medicines Optimisation Centricity. This led to the creation of a White Paper on medicines optimisation. Aspire had no input into the content of the White Paper and reviewed it for factual accuracy and compliance checks only.

References

    1. https://www.england.nhs.uk/medicines-2/medicines-optimisation/
10104511986 v 2.0 October 2023                                 

Aspire Pharma Continues LCCC’s Medical Centre Sponsorship

Aspire Pharma Continues LCCC’s Medical Centre Sponsorship Leicestershire County Cricket Club (LCCC) is delighted to announce Aspire Pharma Ltd as the new sponsor of the club’s state-of-the-art medical centre at
Read More

Aspire Pharma acquires Morningside Pharmaceuticals and Morningside Healthcare and its subsidiaries, including Morningside Healthcare (India) creating the UK’s premier Speciality Pharma company

Aspire Pharma acquires Morningside Pharmaceuticals and Morningside Healthcare and its subsidiaries, including Morningside Healthcare (India) creating the UK’s premier Speciality Pharma company Petersfield, Hampshire, October 3rd 2022, Aspire Pharma Limited,
Read More

Global Licensing rights builds Aspire’s strategic commitment to develop therapies in the prevention of bronchopulmonary dysplasia (BPD) and retinopathy of prematurity (ROP) in preterm infants

Aspire Pharma Ltd, (Petersfield Hampshire), today announced the successful completion of its global licensing agreement of Retinolx , owned by Orphanix GmbH, a privately held, clinical-stage biopharmaceutical company focussed on the
Read More

Aspire welcome its new Chief Executive Officer:

It’s with great pleasure that Aspire officially welcome our new CEO, Richard Condon, to the company. Richard joins us from Bayer UK and as we embark on the next chapter,
Read More
APL1010347H5 October 2023

You are now leaving the Aspire website and being directed to an external website for which Aspire is not responsible.